Monoclonal antibody BCM 43-daunorubicin conjugate

Drug Profile

Monoclonal antibody BCM 43-daunorubicin conjugate

Alternative Names: BCM 43-DNR conjugate

Latest Information Update: 12 Feb 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BCM Oncologia
  • Class Monoclonal antibodies
  • Mechanism of Action DNA intercalators; DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ovarian cancer

Most Recent Events

  • 19 Jan 2000 Preclinical development for Ovarian cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top